A promising ultrasound therapy to potentially restore brain function in people with Alzheimer's disease has been licenced to a new startup spun out of Â鶹ÊÓƵ of Queensland.
The therapeutic ultrasound technology developed by from Â鶹ÊÓƵ’s will be progressed toward clinical use by Ceretas, with the company aiming to validate the system to treat Alzheimer’s and other neurodegenerative diseases.
The technology uses targeted pressure waves from sound to activate the brain’s ability to increase neuronal signalling and clear pathological proteins that accumulate in people with Alzheimer’s disease.
“The therapy increases neuronal signalling and thereby restores memory and cognition by enhancing communication between brain cells,” Professor ³Òö³Ù³ú said.
“But it also targets and clears the build-up of the proteins toxic amyloid and tau by activating the brain’s intrinsic clearance mechanism.”
The global incidence of dementia is predicted to reach 82 million by 2030 with an estimated 80 per cent of people with dementia having Alzheimer's, characterised by cognitive impairment and memory loss.
.jpg)
Professor ³Òö³Ù³ú said current medications target disease progression and symptoms but don’t offer patients a cure.
“Therapeutic ultrasound offers a non-invasive way of enhancing cognition,” he said.
“The treatment could also potentially be personalised across multiple neurological disorders including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), disorders caused by brain tumours and mental disorders.”
The first human clinical safety trial of the novel ultrasound medical device was successfully completed in 2024, led by QBI clinician-researcher .
The trial results are expected to be published in early 2025.
Ceretas was formed by Â鶹ÊÓƵ’s commercialisation company in partnership with early-stage investors and co-founders Ryan Laws and Sam Wetzler.
Mr Laws said taking the therapeutic ultrasound treatment further was an exciting prospect.
“It’s not often that you see potentially game-changing technology coupled with brilliant people, looking to address a market that only seems to set to expand so this opportunity has me very excited,” Mr Laws said.
UniQuest CEO Dr Dean Moss said it was gratifying to see the therapeutic ultrasound technology progress to the clinic with investor backing.
“With an ageing population leading to an increase in neurodegenerative diseases like Alzheimer's, it is testament to the quality of Â鶹ÊÓƵ research that potential new treatments are attracting investment to make a genuine difference,” Dr Moss said.
Image above left: Professor Jürgen ³Òö³Ù³ú.
Media contact
Â鶹ÊÓƵ Communications
communications@uq.edu.au
+61 429 056 139
